NASDAQ:VYGR Voyager Therapeutics (VYGR) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free VYGR Stock Alerts $9.31 -0.25 (-2.62%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$9.20▼$9.6850-Day Range$7.15▼$10.3552-Week Range$6.06▼$14.34Volume628,759 shsAverage Volume960,263 shsMarket Capitalization$505.53 millionP/E Ratio3.01Dividend YieldN/APrice Target$19.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Voyager Therapeutics alerts: Email Address Voyager Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside107.7% Upside$19.33 Price TargetShort InterestHealthy4.25% of Shares Sold ShortDividend StrengthN/ASustainability-0.97Upright™ Environmental ScoreNews Sentiment0.70Based on 13 Articles This WeekInsider TradingSelling Shares$27,272 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.64) to ($1.49) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.67 out of 5 starsMedical Sector74th out of 938 stocksBiological Products, Except Diagnostic Industry13th out of 152 stocks 3.4 Analyst's Opinion Consensus RatingVoyager Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.33, Voyager Therapeutics has a forecasted upside of 107.7% from its current price of $9.31.Amount of Analyst CoverageVoyager Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.25% of the outstanding shares of Voyager Therapeutics have been sold short.Short Interest Ratio / Days to CoverVoyager Therapeutics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Voyager Therapeutics has recently increased by 2.21%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldVoyager Therapeutics does not currently pay a dividend.Dividend GrowthVoyager Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVoyager Therapeutics has received a 71.33% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Voyager Therapeutics is -0.97. Previous Next 2.6 News and Social Media Coverage News SentimentVoyager Therapeutics has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Voyager Therapeutics this week, compared to 5 articles on an average week.Search Interest24 people have searched for VYGR on MarketBeat in the last 30 days. This is an increase of 243% compared to the previous 30 days.MarketBeat FollowsOnly 64 people have added Voyager Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Voyager Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,272.00 in company stock.Percentage Held by InsidersOnly 4.70% of the stock of Voyager Therapeutics is held by insiders.Percentage Held by Institutions48.03% of the stock of Voyager Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Voyager Therapeutics are expected to grow in the coming year, from ($1.64) to ($1.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Voyager Therapeutics is 3.01, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 144.39.Price to Earnings Ratio vs. SectorThe P/E ratio of Voyager Therapeutics is 3.01, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 241.39.Price to Book Value per Share RatioVoyager Therapeutics has a P/B Ratio of 1.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About Voyager Therapeutics Stock (NASDAQ:VYGR)Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.Read More VYGR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VYGR Stock News HeadlinesMarch 27, 2024 | investorplace.comThe Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your PortfolioMarch 27, 2024 | americanbankingnews.comVoyager Therapeutics (NASDAQ:VYGR) Now Covered by Analysts at GuggenheimMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 26, 2024 | globenewswire.comVoyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 25, 2024 | news.yahoo.comCarl Sagan in 1986: 'Voyager has become a new kind of intelligent being—part robot, part human'March 23, 2024 | americanbankingnews.comHead-To-Head Comparison: Voyager Therapeutics (NASDAQ:VYGR) vs. Outlook Therapeutics (NASDAQ:OTLK)March 23, 2024 | sports.yahoo.comKnights fair well in 2-0 loss to VoyagerMarch 22, 2024 | fool.comVoyager Therapeutics (NASDAQ: VYGR)March 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 22, 2024 | americanbankingnews.comResearch Analysts Issue Forecasts for Voyager Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:VYGR)March 21, 2024 | investorplace.comCheap Thrills: 7 Promising Value Stocks You Can Buy for Under $20March 21, 2024 | americanbankingnews.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Forecasted to Post Q1 2025 Earnings of ($0.32) Per ShareMarch 20, 2024 | americanbankingnews.comVoyager Therapeutics (NASDAQ:VYGR) Now Covered by HC WainwrightMarch 19, 2024 | msn.comAnalyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine PlatformMarch 19, 2024 | usatoday.comVoyager 1 is 15 billion miles from home and broken. Here's how NASA is trying to fix it.March 16, 2024 | msn.comNASA scientist viewed first Voyager images. What he saw gave him chills.March 15, 2024 | msn.comNASA's Voyager 1 Spacecraft made a little sense for the first time in monthsMarch 15, 2024 | usatoday.comNASA gave Voyager 1 a 'poke' amid communication woes. Here's why the response was encouraging.March 15, 2024 | msn.comNASA Is One Step Closer to Fixing Voyager 1March 15, 2024 | msn.comThe Voyager’s Golden Record: Real-Life Inspiration Behind Netflix’s The SignalMarch 15, 2024 | forbes.comAiling Voyager 1 Spacecraft Offers Glimmer Of Hope To NASAMarch 14, 2024 | msn.comA cosmic ‘poke’ by NASA receives surprising response from Voyager 1March 14, 2024 | msn.comVoyager 1 starts making sense again after months of babbleMarch 14, 2024 | yahoo.comVoyager 1 Sputters Back to LifeMarch 14, 2024 | msn.comNASA finds clue while solving Voyager 1's communication breakdown caseMarch 14, 2024 | yahoo.comVoyager, Chandrayaan, Curiosity: How do spacecraft get their names?March 13, 2024 | seekingalpha.comVoyager Therapeutics: On Track To Deliver High Returns On InvestmentSee More Headlines Receive VYGR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today3/29/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VYGR CUSIPN/A CIK1640266 Webwww.voyagertherapeutics.com Phone(857) 259-5340FaxN/AEmployees162Year FoundedN/APrice Target and Rating Average Stock Price Target$19.33 High Stock Price Target$30.00 Low Stock Price Target$14.00 Potential Upside/Downside+107.7%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)$3.09 Trailing P/E Ratio3.01 Forward P/E RatioN/A P/E GrowthN/ANet Income$132.33 million Net Margins52.93% Pretax Margin53.49% Return on Equity63.89% Return on Assets40.79% Debt Debt-to-Equity RatioN/A Current Ratio4.96 Quick Ratio4.96 Sales & Book Value Annual Sales$250.01 million Price / Sales2.02 Cash Flow$2.95 per share Price / Cash Flow3.16 Book Value$5.37 per share Price / Book1.73Miscellaneous Outstanding Shares54,300,000Free Float51,749,000Market Cap$505.53 million OptionableOptionable Beta0.96 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Alfred W. Sandrock Jr. (Age 66)M.D., Ph.D., President, CEO & Director Comp: $825.41kMr. Peter P. Pfreundschuh CPA (Age 55)Chief Financial Officer Comp: $172.73kDr. Guangping Gao Ph.D.Founder & Member of Scientific Advisory BoardDr. Mark A. Kay M.D. (Age 65)Ph.D., Founder Dr. Phillip D. Zamore Ph.D.Founder & Member of Scientific Advisory BoardMs. Robin Swartz (Age 52)COO & Acting Chief Business Officer Mr. Todd Carter Ph.D. (Age 54)Chief Scientific Officer Ms. Jacquelyn Fahey Sandell Esq.J.D., Chief Legal OfficerMs. Michelle Quinn SmithChief Human Resources OfficerMr. G. Andre Turenne (Age 50)Advisor Comp: $600.3kMore ExecutivesKey CompetitorsFate TherapeuticsNASDAQ:FATEHarpoon TherapeuticsNASDAQ:HARPGracell BiotechnologiesNASDAQ:GRCLIcosavaxNASDAQ:ICVXAdverum BiotechnologiesNASDAQ:ADVMView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 47,711 shares on 3/11/2024Ownership: 4.659%Goldman Sachs Group Inc.Bought 38,906 shares on 3/1/2024Ownership: 0.409%Price T Rowe Associates Inc. MDSold 169,301 shares on 2/16/2024Ownership: 2.284%Vanguard Group Inc.Bought 47,711 shares on 2/15/2024Ownership: 5.751%Citadel Advisors LLCSold 8,300 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions VYGR Stock Analysis - Frequently Asked Questions Should I buy or sell Voyager Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VYGR shares. View VYGR analyst ratings or view top-rated stocks. What is Voyager Therapeutics' stock price target for 2024? 7 Wall Street research analysts have issued twelve-month target prices for Voyager Therapeutics' shares. Their VYGR share price targets range from $14.00 to $30.00. On average, they expect the company's stock price to reach $19.33 in the next year. This suggests a possible upside of 107.7% from the stock's current price. View analysts price targets for VYGR or view top-rated stocks among Wall Street analysts. How have VYGR shares performed in 2024? Voyager Therapeutics' stock was trading at $8.44 on January 1st, 2024. Since then, VYGR shares have increased by 10.3% and is now trading at $9.31. View the best growth stocks for 2024 here. When is Voyager Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our VYGR earnings forecast. How were Voyager Therapeutics' earnings last quarter? Voyager Therapeutics, Inc. (NASDAQ:VYGR) issued its quarterly earnings data on Wednesday, February, 28th. The company reported $1.25 earnings per share for the quarter, beating analysts' consensus estimates of ($0.59) by $1.84. The business earned $90.06 million during the quarter, compared to analyst estimates of $4.95 million. Voyager Therapeutics had a net margin of 52.93% and a trailing twelve-month return on equity of 63.89%. What ETF holds Voyager Therapeutics' stock? iShares Neuroscience and Healthcare ETF holds 4,243 shares of VYGR stock, representing 0.82% of its portfolio. What other stocks do shareholders of Voyager Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include Micron Technology (MU), REGENXBIO (RGNX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Amarin (AMRN), CRISPR Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO) and Editas Medicine (EDIT). Who are Voyager Therapeutics' major shareholders? Voyager Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Armistice Capital LLC (9.63%), Vanguard Group Inc. (5.75%), Vanguard Group Inc. (4.66%), Price T Rowe Associates Inc. MD (2.28%), Price T Rowe Associates Inc. MD (2.28%) and Dimensional Fund Advisors LP (2.12%). Insiders that own company stock include Alfred Sandrock, Ecor1 Capital, Llc, Glenn Pierce, Julie Burek, Neurocrine Biosciences Inc, Omar Khwaja, Peter P Pfreundschuh, Robert W Hesslein, Robin Swartz, Rock Ventures Iii LP Third and Todd Alfred Carter. View institutional ownership trends. How do I buy shares of Voyager Therapeutics? Shares of VYGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VYGR) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyager Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.